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Amyloid-β42Sporadic inclusion-body myositis (s-IBM) is the most common degenerative muscle disease in which aging
appears to be a key risk factor. In this review we focus on several cellular molecular mechanisms responsible
for multiprotein aggregation and accumulations within s-IBM muscle ﬁbers, and their possible consequences.
Those includemechanisms leading to: a) accumulation in the form of aggregateswithin themuscle ﬁbers, of sev-
eral proteins, including amyloid-β42 and its oligomers, and phosphorylated tau in the form of paired helical ﬁl-
aments, and we consider their putative detrimental inﬂuence; and b) protein misfolding and aggregation,
including evidence of abnormalmyoproteostasis, such as increased protein transcription, inadequate protein dis-
posal, and abnormal posttranslational modiﬁcations of proteins. Pathogenic importance of our recently demon-
strated abnormal mitophagy is also discussed. The intriguing phenotypic similarities between s-IBM muscle
ﬁbers and the brains of Alzheimer and Parkinson's disease patients, the two most common neurodegenerative
diseases associated with aging, are also discussed. This article is part of a Special Issue entitled: Neuromuscular
Diseases: Pathology and Molecular Pathogenesis.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Sporadic inclusion-body myositis (s-IBM) is the most common
muscle disease of older persons. The onset of clinical weakness is age-
related, slowly progressive and leading to severe disability. There is no
sustainable treatment available. Initially, s-IBM was considered a rare
muscle disease, but during the last two decades, due to both physicians'
greater awareness of this disease and the existence of more reliable
pathological markers of s-IBM muscle biopsies, diagnosis of s-IBM has
become more prevalent.
The pathogenesis of sporadic inclusion-body myositis (s-IBM) is
complex and involves multidimensional pathways, and several critical
issues are still unresolved.
The known muscle-ﬁber degeneration aspects and mononuclear-
cell inﬂammation are components of the s-IBM pathology, but whichrants (to VA) from theNational
lar Dystrophy Association, The
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. This is an open access article underis precedent and how they interrelate are not certain [1–5]. There is
growing evidence that aging of the muscle-ﬁber, associated with
intra-muscle-ﬁber accumulation of several conformationally-modiﬁed
proteins, plays a primary and major pathogenic role leading to
muscle-ﬁber destruction and clinical weakness.
s-IBM muscle-ﬁber degeneration is characterized by vacuolization
and intra-muscle-ﬁber accumulation of misfolded, ubiquitinated,
congophilic, multiple-protein aggregates [1–3]. We suggest that multi-
ple postranslationally-modiﬁed proteins (see below) accumulated
within the s-IBM aging muscle ﬁbers may be eliciting the T-cell inﬂam-
matory reaction. This may be similar to some older patients with hered-
itary IBM (h-IBM) caused by missense mutations in the UDP-N-
acetylglucosamine-2 epimerase/N-acetylmannosamine-kinase (GNE)
gene, whose muscle biopsies exhibit several similarities to s-IBM biop-
sies and have various degrees of lymphocytic inﬂammation [6–8],
even though that form of h-IBM is considered not basically immune-
mediated [9]. We propose that in older h-IBM patients, the “aging”
muscle-ﬁber environment, and perhaps other individual intrinsic mus-
cle ﬁber abnormalities, make some of the accumulated proteins
interpreted as “foreign” by the immune system, thereby inducing the
component of T-cell lymphocytic inﬂammation. Another hint that in-
ﬂammation might be secondary in human s-IBM is provided by an al-
leged mouse “model of s-IBM” based on overexpression of mutated
gelsolin D187N [10]. In that model, within the myoﬁbers of aged
mouse there were intra-myoﬁber accumulations of misfolded andthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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perivascular and endomysial lymphocytic inﬁltration, suggesting that
inﬂammation in thatmousemodel was secondary to the overexpressed
abnormal mutant protein or other proteins accumulated within the
muscle-ﬁber. The possibility that in s-IBM the inﬂammation might be
a secondary to the ongoing degeneration and production of abnormal
proteins within the muscle-ﬁbers could explain why s-IBM patients,
in contrast to polymyositis patients, whose muscle biopsies express
similar inﬂammatory repertoire, do not satisfactorily respond to various
anti-dysimmune/anti-inﬂammatory treatments that have been exten-
sively tried [4,11–13]. There is a possibility, not yet convincingly proven,
that various cytokines and other putatively toxic products released
from the inﬂammatory cells may contribute to s-IBM pathogenesis
and aggravate the existing degenerative component — a concept
proposed by others [14,15]. Another aspect involves a reported genetic
predisposition to s-IBM involving the HLA-DRB1 genotype, as well as
association of the HLA-A haplotype with earlier disease onset [16,17].
A recent paper reported that polymorphism in the TOMM40 gene inﬂu-
ences the risk of developing s-IBM, as well as the age of disease onset
[18]. TOMM40 encodes the mitochondrial pore protein Tom40, which
is involved in the transport of Aβ and other proteins into mitochondria
[19], and its elongation has been postulated associated with the
pathogenesis of AD [20]. Even though still requiring conﬁrmation,
those studiesmight contribute to better understanding of mitochondri-
al abnormalities in s-IBM, and add to the possible importance of Aβ in s-
IBM pathogenesis.
An increase of non-organ-speciﬁc auto-antibodies, as well as associ-
ation of some autoimmune disorders with approximately 27% of s-IBM
patients was reported [16,21,22]. Auto-antibodies against 5′-nucleotid-
ase have also been reported in s-IBM patients [23,24], but their patho-
genic signiﬁcance is not yet known.Fig. 1. Proposed pathogenic cascade of s-IBM.We propose that aging of themuscle ﬁber intracel
lead to still unknown molecular changes within the muscle ﬁber (indicated in the diagram as
namely: a) existence of several abnormalmechanisms of protein transcription and processing;
cle ﬁber abnormalities (details in the text). We also propose that Aβ42 and its oligomers, as w
leading to muscle ﬁbers atrophy, weakness, and death (details in the text).Here we describe several molecular abnormalities occurring in s-
IBM muscle ﬁbers, which, in our opinion, importantly contribute to
the s-IBMpathogenesis. These include: 1. Abnormal accumulationwith-
in s-IBM muscle ﬁbers of multiprotein congophilic aggregates, which
apparently result from a) increased transcription of several proteins,
b) their abnormal posttranslational modiﬁcations and misfolding, and
c) inadequate protein disposal. These phenomena indicate abnormali-
ties of muscle protein homeostasis, also called “myoproteostasis” [25].
We propose that abnormal myoproteostasis might be provoked or ag-
gravated by an aging intracellular milieu. 2. Consequences of impaired
autophagy leading to accumulation of Aβ42 and its oligomers. 3. Abnor-
malities of mitophagy putatively have a pathogenic role contributing to
the mitochondrial abnormalities. Fig. 1 illustrates our current proposed
cascade of s-IBM pathogenesis.
Experimental evidence indicating strong relationships among
various pathologic pathways were recently described in detail
[25], stressing the complex, interwoven pathogenic cascade of s-
IBM.
Interesting phenomena involving degeneration of s-IBM muscle
ﬁbers are several similarities to the complex neuronal degenerations oc-
curring both in Alzheimer (AD) and Parkinson (PD) brain diseases.
These include: a) abnormal accumulations of many of the same puta-
tively pathogenic proteins; b) similar posttranslational modiﬁcations
of the accumulated proteins; c) similarly defective mechanisms of
protein disposal, including inhibition of both the 26S proteasome and
autophagy; and d) mitochondria abnormalities (detailed and refer-
enced in [2,26,27]).
Accordingly s-IBM, similarly to AD and PD, is considered a “confor-
mational disorder”, caused by protein unfolding/misfolding and associ-
ated with the formation of ubiquitinated multiprotein inclusion-bodies
(aggregates) (reviewed and referenced in [2,5,26]).lularmilieu, predisposing genes, and possibly some other aspects of themuscle-cellmilieu,
a black box with a question mark). This subsequently leads to several detrimental events,
and b) accumulations of several proteins. These constitute the typical proﬁle of s-IBMmus-
ell as an inhibition of protein-disposal and mitochondrial abnormalities are key factors
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regeneration ability of muscle ﬁbers [28]. Whether a defective ability
of s-IBM muscle-ﬁber to regenerate partly relates to aging or other
factors is not yet known [28,29].
Several reviews address clinical features of s-IBM, which are charac-
terized by severe weakness of the quadriceps and forearmsmuscles, in-
cluding severe weakness of ﬁnger ﬂexors and extensors [4,12,13,21,30].
To diagnose s-IBM, there are no universally accepted serological
tests. Even though antibodies against 5′-nucleotidase have been
described by two groups and proposed to be a diagnostic marker for
s-IBM [23,24], they are reported, depending on the study, in less than
50% of s-IBM patients. Furthermore, several non-s-IBM patients have
positive 5′-nucleotidase antibodies [15]. Hence, the validity of those an-
tibodies for s-IBM diagnosis awaits conﬁrmation, and their pathogenic
signiﬁcance is not known.
Previously, increased serum amyloid-β 42 (Aβ42) was reported to
be present in s-IBM, but not in polymyositis patients; however, that
test has not received further consideration, probably because Aβ42
was also increased in a few older patients with previously, but possibly
not correctly diagnosed “dermatomyositis” [31].
Currently, we consider that the most important diagnostic aspect of
s-IBM is proper evaluation of the muscle biopsy.
2. Diagnostic criteria of the s-Ibm muscle biopsy
Examples of the most typical abnormalities found in s-IBM muscle
biopsies were recently described in details and illustrated [25–27].
Below,we provide a brief summary of themost characteristic diagnostic
features.
2.1. Light-microscopy
2.1.1. Vacuolated muscle ﬁbers
The characteristic feature of s-IBMon theEngel-trichrome staining is
muscle ﬁbers containing one or a few vacuoles in a given cross-section.
Most of the vacuoles appear to be autophagic because they contain
bluish-reddish material within the vacuoles or at their periphery,
indicating lipoprotein membranous material.
2.1.2. Intracellular amyloid deposits
2.1.2.1. Congo-red staining.Multiple or single foci of β-pleated sheet am-
yloid, as identiﬁed by Congo-red ﬂuorescence visualized through Texas-
red ﬁlters, are evident within about 40–70% of the s-IBM vacuolated
muscle ﬁbers in a given transverse section, mostly in their non-
vacuolated regions.
2.1.2.2. Crystal violet. Crystal violet metachromatic staining can also
show the intra-myoﬁber amyloid deposits in s-IBM muscle ﬁbers.
While this method is more convenient because it does not require ﬂuo-
rescence microscopy, it is less precise because small amyloid deposits
can be difﬁcult to identify. Accordingly, we do not recommend this
stain for routine evaluation of s-IBM muscle biopsies.
2.1.3. Intra-muscle ﬁber clusters of p62/SQTSM-immunopositive PHFs
p62/SQSTM1, or simply “p62”, is a shuttle protein transporting
polyubiquitinated proteins for both proteasomal and lysosomal degra-
dation (details below). In s-IBMmuscle ﬁbers p62 is an integral compo-
nent of paired helical ﬁlaments (PHFs) that contain phosphorylated tau
(p-tau). The staining appears in the form of strongly-immunoreactive,
various-sized, mainly squiggly, linear or small rounded aggregates.
These are usually in the vacuole-free cytoplasm of approximately 80%
of the vacuolated muscle ﬁbers, and in about 20–25% of the muscle ﬁ-
bers that appear “non-vacuolated” on a given 10 μm transverse section.
Usefulness of p62 in immunocytochemical diagnosis of s-IBM was re-
cently also emphasized by others [32].2.1.4. Negative alkaline phosphatase (AP) staining of connective tissue
In s-IBM muscle biopsies, perimysial connective tissue, even in
regions of active disease, lacks the typically-strong AP-positivity seen
in similarly-active regions of polymyositis (PM) and dermatomyositis
(DM) biopsies — we attribute this activity to active ﬁbroblasts [refer-
enced in [4]]. It is a convenient and inexpensive stain to differentiate
between s-IBM and PM [4].
2.1.5. Staining with novel ﬂuorescent amyloid ligands
Fluorescent amyloid ligands termed luminescent conjugated
oligothiophenes (LCOs), rapidly andwith high sensitivity detect protein
inclusions in s-IBM muscle ﬁbers [33]. Their use requires ﬂuorescence
microscopy, and they are not yet commercially available, to our knowl-
edge. However, the easiness of their use and high sensitivity should
make them very attractive in the future.
2.1.6. Typical but not diagnostic abnormalities
2.1.6.1. COX-negative ﬁbers and ragged-red ﬁbers. Characteristic, but not
diagnostic of s-IBM, are cytochrome oxidase (COX)-negative muscle
ﬁbers and ragged-red ﬁbers — both those abnormalities are occurring
more often in s-IBM as compared to aged-matched normal controls
[34].
2.1.6.2. TDP-43 immunoreactivity. Transactive response DNA-binding
protein 43 (TDP-43) is immunoreactive within s-IBM muscle ﬁbers in
the form of cytoplasmic inclusions, and reported to be diagnostic, even
though they were not present in a signiﬁcant number s-IBM muscle
biopsies [35,36]. However, ﬁbers positive for p62-inclusions were re-
ported three-times more frequent than ones containing TDP-43-
inclusions [37]. Moreover, p62-inclusions were more sharply deﬁned,
and two biopsies displaying several p62 inclusions did not contain any
TDP43-inclusions. Therefore, we do not recommend TDP-43 for diag-
nostic evaluation of s-IBM biopsies.
2.2. Electron-microscopy
Previously, electron-microscopic (EM) identiﬁcation of PHFs was
considered important for s-IBM diagnosis. Now, because of the avail-
ability of new histochemical and immunohistochemical markers, that
importance has diminished. For example, following staining with the
antibodies against p62 or p-tau, typical clusters of PHFs are easily
visualized by light microscopy — these we have demonstrated by EM-
immunocytochemistry strongly associated with PHFs.
3. General pathogenic considerations
In our opinion, it is becoming more evident that in s-IBM a unique
type of muscle-ﬁber degeneration leads to muscle-ﬁber atrophy, and
also resulting in muscle ﬁber degeneration and death — these are
manifesting clinically by inexorably progressive muscle weakness.
Presumably, the demonstrated 26S proteasome and autophagy
inhibitions contribute to the observed abnormal protein aggregates, β-
pleated sheet amyloid accumulation, and cytoplasmic vacuolization.
Abnormal accumulation of ubiquitinated intracellular proteinacious
congophilic inclusions is characteristic of the s-IBM phenotype —
accordingly, s-IBM, similarly to AD and PD, is considered a “conforma-
tional disorder” caused by protein unfolding/misfolding and associated
with the formation ofmultiprotein inclusion-bodies (reviewed in [1,3,5]).
As with AD and PD brains, in s-IBM muscle ﬁbers the sequence of detri-
mental pathologic events comprising cellular degeneration is not well
delineated. Even though it is not clear whether protein-aggregates them-
selves impair normal cellular functions, it is very likely that they are det-
rimental to the muscle ﬁber, because masses of aggregates – which are
visible in many muscle ﬁbers on a given transverse section and known
to be present in various places along the muscle ﬁbers – could severely
636 V. Askanas et al. / Biochimica et Biophysica Acta 1852 (2015) 633–643impair muscle ﬁber integrity and mechanical function. Large aggregates
can physically displace and disturb the function of normal cytoplasmic
proteins and organelles, such as mitochondria and endoplasmic reticu-
lum. Proteins that accumulatewithin the aggregates often showoxidative
damage [38], which may have been caused them to be incorporated
there. Oxidative and nitrotyrosine stress occurs in s-IBM muscle ﬁbers
[39,40] — and both affect assembly and phosphorylation of tau [41,42],
and probably damage various other proteins, thereby impairing muscle-
ﬁber function.
Belowwe describe themost recent research directed toward under-
standing the mechanisms causing impaired protein degradation,
proteinmolecular modiﬁcations, abnormal protein aggregation, and re-
lated consequences. Also discussed are our newest ﬁndings related to
abnormal mitophagy. The putative pathogenic importance of the endo-
plasmic reticulum stress that we have identiﬁed in s-IBM muscle has
been previously discussed [25,26].
4. Abnormal myoproteostasis
In normal cells, quality-control mechanisms assure that any dam-
aged or malfunctioning intracellular structures, including proteins and
organelles, are identiﬁed and repaired, or removed (reviewed in [43,
44]). The cellularmechanisms for ensuring proper protein “quality-con-
trol” also inﬂuence protein transcription, thereby preventing proteins
from being over- or under-produced. To eliminate misfolded proteins,
a cell utilizes: a) protein refolding through the endoplasmic reticulum
(ER)-chaperones; b) protein refolding through heat shock proteins;
c) protein degradation through the 26S ubiquitin-proteasome system
(UPS); and d) protein degradation through autophagy. Under various
pathological conditions, and in aging, protein quality-control is
disturbed (reviewed in [43,45]). This results in accumulation and aggre-
gation of pathologically modiﬁed proteins and damaged organelles.
The term “proteostasis” describes the integrated cellular network
that controls the life of proteins from their initiation to termination [46,
47]. Proteostasis is considered a broader term than “protein quality-
control” because it encompasses regulation of protein transcription,
translation, folding, processing, assembly/disassembly and degradation
[46,47]. Although some abnormal aspects of proteostasis are present in
every abnormal cell, abnormal proteostasis is considered especially im-
portant in several neurodegenerative diseases of brain [46] and in s-
IBM muscle ﬁbers, where accumulated protein aggregates contain vari-
ous proteins in different stages of abnormal proteostasis [25].
Among several proteins (details reviewed in [26]),we here focus only
on a few likely to be pathogenically most important in s-IBM. Conceptu-
ally, proteins identiﬁed as increased or immunocytochemically-present
in an aggregate could be the result of their i) overproduction, ii) impaired
catabolism (related to proteasome or lysosome inadequacy), or iii) post-
translational modiﬁcation, including being “attached” to other accumu-
lated proteins. Accumulated proteins a) might have abnormal structure
causing their aggregation, or b) might have their normal cellular
structure, and/or function, but are “captured” into an aggregate of an ab-
normal protein. Collectively, we apply to them the term “abnormal
myoproteostasis”.
4.1. Increased transcription and accumulation of amyloid-β precursor
protein (AβPP), and abnormalities of AβPP processing, involving BACE1
and γ-secretase complex
s-IBM muscle ﬁbers have increased mRNA of AβPP-751 [48], the
most abundant form in the peripheral tissues [49]. The underlyingmech-
anism of the AβPP overproduction in s-IBM is not yet clariﬁed. In addi-
tion, AβPP in s-IBM muscle ﬁbers is posttranslationally modiﬁed, as
evidenced by its increased phosphorylation [50]. Importantly, there are
also distinct abnormalities in AβPP processing, including increased tran-
scription and accumulation of BACE1 (β-site amyloid-β precursor pro-
tein cleaving enzyme) [26,51], which cleaves AβPP at the N-terminal ofAβ [52], and increased levels of BACE1-antisense (BACE1-AS) transcript
[51], a non-coding RNA that regulates BACE1mRNA and protein expres-
sion in vivo and in vitro, and was reportedly also increased in AD brains
[53]. It would be of interest to studywhether other non-coding RNAs are
accumulated in s-IBMmuscleﬁbers. The importance of non-coding RNAs
in various pathological processes was recently reviewed [54].
Also demonstrated were increased transcription and accumulation
of the components of the γ-secretase system [55], which cleaves AβPP
at the C-terminal of Aβ to generate either Aβ40 or Aβ42 (reviewed in
[56]). Additionally, Nicastrin, a component of the γ-secretase complex,
is strongly hyperglycosylated in s-IBM, indicating its posttranslational
modiﬁcation [55]. Other factors likely contributing to Aβ production,
deposition and oligomerization, such as cystatin C, transglutaminases
1 and 2, and cholesterol are also increased in s-IBM muscle ﬁbers (de-
tails in [3,26]). Accordingly, transcription of AβPP combined with the
milieu within the s-IBM muscle ﬁber is a facilitating environment for
Aβ production and accumulation.
4.2. Accumulation of Aβ42 and evidence of putatively toxic Aβ42 oligomers
Our studies of s-IBM muscle biopsies more than two decades ago
were the ﬁrst to identify an intracellular accumulation of Aβ in any dis-
ease [57,58] They were the basis for our proposal of an important cyto-
toxic role of intra-cellular Aβ, not only for s-IBM muscle ﬁbers but, by
analogy, suggested also for AD neurons [59]. Previously for years it had
been considered that only extracellular Aβ is detrimental in AD brain
[60]. Now, however, the presence of intraneuronal Aβ is well established
and its possible toxicity and importance in the ADpathogenesis are being
considered (reviewed in [46,61,62].
In s-IBM muscle ﬁbers, Aβ42 is the form associated with the Congo-
red-positive amyloid inclusions [63]. Recently, we have shown that
dysferlin is a newbinding partner of Aβ42 [64]. This is of particular inter-
est, because in s-IBM dysferlin was absent or greatly decreased from its
normal location at the periphery of themuscleﬁbers, butwas accumulat-
ed, together with Aß42, within themuscle ﬁbers in the form of large ag-
gregates [64]. Since genetically-dysferlin-deﬁcient patients often have
inﬂammation in their muscle biopsies [65], one can wonder whether
a) dysferlin absence from the periphery of s-IBM muscle ﬁbers might
contribute to s-IBM inﬂammatory reaction, or b) perhaps the pre-
aggregated dysferlin protein molecule is subtly altered so as to make it
“foreign” to the patient's immune system.
The putative importance of Aβ42 cytotoxicity in s-IBM muscle ﬁbers
is strengthened by our demonstration of actual Aβ42 oligomers in them
[66]. In general, cytotoxicity of Aβ is considered to depend on its initial
assembly into detrimental oligomers. In contrast to Aβ monomers,
which in other systems are considered not cytotoxic (recently reviewed
in [61,62]), small oligomers and protoﬁbrils are thought to be the cyto-
toxic forms of Aβ42 [46,61,62,67]. In s-IBM muscle biopsies, Aβ42-
dimers, -trimers and -tetramers were evident by immunoblots [66],
thereby providing additional evidence that intra-muscle-ﬁber accumula-
tion of Aβ42 oligomers may contribute importantly to the s-IBM patho-
genic cascade. Nonﬁbrillar, cytotoxic “Aβ-Derived Diffusible Ligands”
(ADDLs), originally derived from Aβ42 [67], were shown increased in
AD brain and proposed to play an important pathogenic role [67], and
were also increased in s-IBMmuscle [66]. (Actually, the principle of a cy-
totoxicity of soluble, ultrastructurally-invisible pre-ﬁbrillar abnormal
amyloidogenic proteins was postulated 3 decades ago for extracellular
amyloidoses [68]).
4.3. Phosphorylated tau
In s-IBM muscle ﬁbers, as in AD brain [69,70], p-tau is accumulated
intracellularly in the form of congophilic, squiggly or linear inclusions
[3,25,26,71], which is identiﬁed by various antibodies [71,72], recogniz-
ing several of the same epitopes of p-tau that are present in ADbrain, in-
cluding ones speciﬁcally identifying “AD-speciﬁc” conformational tau
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(PHFs). Several kinases known to phosphorylate tau [69,70] are also
accumulated within s-IBM muscle ﬁbers, where they co-localize
with p-tau-positive inclusions. These include extracellular signal-
regulated kinase (ERK), CDK5 (reviewed in [26]), glycogen synthase
kinase 3β (GSK-3β), and casein kinase 1 [75]. Also, GSK-3β is
hyperphosphorylated and activated in s-IBM muscle ﬁbers [50].
s-IBM-PHFs also contain RNA and the RNA-binding-protein Survival
Motor Neuron (SMN), both of which were proposed to contribute to
PHF formation [76]. Studies related to neurodegeneration strongly
suggest that intracellular increase of p-tau is cytotoxic to neurons
(reviewed in [70,77]). Recently, it has been reported that in AD brain
p-tau is hyperacetylated due to deﬁciency of SIRT1 [78]. That modiﬁca-
tion was reported to impair p-tau degradation by the 26S proteasome
[78]. Impaired autophagy has also been implicated as a factor contribut-
ing to tau oligomerization and accumulation [79]. It is possible that
Aβ42-oligomers, impaired functions of both the 26S proteasome and
autophagy, and decreased SIRT1 activity, all identiﬁed in s-IBM muscle
ﬁbers [63,66,80,81], contribute to abnormal tau phosphorylation in s-
IBM. It has also been proposed that Aβ can trigger conversion of tau
into a toxic state and, in turn, toxic tau enhances Aβ toxicity [82]. As
both proteins co-exist in s-IBM muscle ﬁbers, it is quite possible that
their pathologic interaction occurs in s-IBM.
Several other proteins are also accumulatedwithin the bundles of p-
tau-containing PHFs (referenced in [26]), and it is possible that multiple
clusters of PHFs might signiﬁcantly displace and impair the function of
other cytoplasmic proteins and organelles, such as mitochondria and
endoplasmic reticulum. Also, pre-aggregated abnormal misfolded tau
molecule might have an invisible, submicroscopic “sticky” cytotoxicity
(see above).
4.4. Myostatin (MSTN)
MSTN, a protein secreted from skeletal muscle, is considered a neg-
ative regulator of muscle growth during development and of muscle
mass during adulthood [83]. In biopsied s-IBMmuscle ﬁbers,MSTN pre-
cursor protein (MSTNPP) and MSTN dimers are signiﬁcantly increased
on immunoblots, and MSTNPP immuno-co-localizes with Aβ/AβPP
[84].
Interestingly, AβPP-overexpression into cultured normal humanmus-
cleﬁbers increasedMSTNPP expression, and subsequent experimental in-
hibition of proteasome caused accumulation and colocalization of both
MSTNPP/myostatin and AβPP/Aβ, and their physical association [85].
The mechanism(s) by which overexpressed AβPP/Aβ increases MSTNPP
is not known. Possibly, AβPP binding to MSTNPP causes its posttransla-
tionalmodiﬁcation that lessens its trafﬁc and degradation, resulting in ac-
cumulation — it is unknown whether in that hypothetical situation
myostatin would retain its deleterious effect on muscle ﬁbers.
Recently, the importance ofMSTNPP accumulation in s-IBMwas em-
phasized by the studies of others [86] demonstrating thatMSTNPP is ca-
pable of forming intracellular β-pleated sheet amyloid. Since MSTN
physically associateswith Aβ [84,85], it is possible, aswe have previous-
ly proposed [84], that these two proteins might enhance each other's
aggregation, oligomerization and β-pleated sheet formation.
4.5. α-Synuclein
α-Synuclein (α-syn) is a protein of poorly understood normal cellular
function. It is a major component of Lewy bodies (LB) in PD brain
(reviewed in [87,88]).
Abnormal expression ofα-syn occurring spontaneously in thebrains
of various neurodegenerative disorders, including AD brain, has been
associated with, and possibly causative of, oxidative stress, impaired
proteasome function, and mitochondrial abnormalities [87]. Oxidative
stress can induce aggregation of α-syn into amyloid-like ﬁbrils [87].In s-IBM muscle α-syn is also increased, by immunohistochemistry
and immunoblots [89,90], and its mRNA is increased by real-time PCR,
suggesting its increased production (Nogalska et al., 2011, unpub-
lished). In s-IBM muscle, the increased α-syn might also be due to its
decreased degradation. α-syn is degraded by both 26S proteasome
and autophagy (recently reviewed in [91]), both of which are impaired
in s-IBM muscle ﬁbers [80,81]. Moreover, abnormalities of chaperone
mediated-autophagy (CMA), an important pathway of α-syn degrada-
tion, have recently been reported in s-IBM muscle ﬁbers [92].
α-syn has been shown to be associated with mitochondria, and its
overexpression induced mitochondria abnormalities (reviewed in [93]
). Because oxidative- and nitric-oxide-induced stresses, and mitochon-
drial abnormalities, are also aspects of the s-IBMmuscle-ﬁber pathology
([39,40], and reviewed in [2,26] and below), a putative toxicity ofα-syn
may contribute to the muscle-ﬁber degeneration. Recently, α-syn was
reported to directly stimulate tau phosphorylation through activation
of GSK-3β [94].
5. Abnormal protein disposal
Unfolding or misfolding of proteins can occur in vivo and in vitro
under several circumstances, including macromolecular crowding,
defective protein disposal, oxidative stress, and “aging”. Intracellular
mechanisms intended to maintain a proper quality and balance of pro-
teins and organelles try to assure that any malfunctioning or damaged
intracellular structures, including proteins and organelles, are identiﬁed
and repaired or cleared (reviewed and referenced in [26,43,91]. This
control or surveillance machinery is particularly important for the
non-dividing post-mitotic cells like neurons or muscle ﬁbers, because
their accumulated abnormal proteins cannot be diluted during cell divi-
sion [91]. Under various pathological conditions and in aging, protein
quality-control is disturbed (reviewed in [46,91,95]).
In eukaryotic cells, two major pathways of cellular protein degrada-
tion relate to the 26S proteasome and the autophagic/lysosomal
systems [43,91,95]. The 26S proteasome, also called the ubiquitin-
proteasome system (UPS), is a major degradation mechanism for:
a) normal regulatory and other short-lived proteins, and b) misfolded
proteins exported from the endoplasmic reticulum (ER) through a
ubiquitin-mediated ATP-independent process [43]. In contrast, long-
lived, structural proteins and/or variously damaged or misfolded pro-
teins, abnormal mitochondria and other obsolescent cellular organelles
are degraded through “autophagy” [91,95].
5.1. Impairment of the 26S proteasome function in s-IBM muscle ﬁbers
In s-IBMmuscle ﬁbers, our studies demonstrated proteasome impair-
ment as evidenced by reduced activities of the three major proteasomal
proteolytic enzymes [80]. Our experimental studies suggested that
AβPP/Aβmay inhibit proteasome function [80]. Other factors present in
s-IBMmuscle ﬁbers that might contribute to inhibiting proteasome func-
tion include: an agingmuscle-ﬁber environment; protein over-crowding;
oxidative stress; and accumulated p-tau, α-synuclein, and UBB+1 [96]—
all of these are capable of inhibiting proteasome activity in other systems
(referenced in [26]).
A failure to degrade/remove unnecessary proteins, including various
abnormal damaged proteins, is presumably as detrimental to muscle ﬁ-
bers as it is to other cells. For example, accumulated ubiquitinated,
misfolded, and oxidized proteins aggregate by themselves and can
cause proteasome inhibition, and might do so in their pre-aggregated
phase. It ismore likely that the still-soluble, early intermediates of protein
aggregates, in the formof dimers and trimers, can also induce proteasome
inhibition, and some are known to be highly toxic to cells. There are other
diverse functions controlled by the ubiquitin-proteasome system (UPS),
including regulation of gene transcription through monoubiquitination
and deubiquitination of histones, and presentation ofmajor histocompati-
bility complex I (MHCI) (reviewed in [97]). Whether proteasomal
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IBMmuscle ﬁbers is not known.5.2. Impaired autophagy in s-IBM muscle ﬁbers
Autophagic pathways are composed of three main components 1)
macroautophagy, 2) chaperone-mediated-autophagy (CMA), and 3)
microautophagy, all of which lead to cargo degradation within the lyso-
somes (reviewed in [91,98,99]). Lysosomes comprise the main compart-
ment in which degradation of various proteins and other molecules
actually occurs, through the activity of various lysosomal enzymes.
When the lysosomal function is inhibited, there is proliferation and en-
largement of autophagosomes “cargo-shiplets”, which constitute the
route by which the cargo is transferred to the lysosomes, because the
cargo that they are carrying cannot be received and cleared by the lyso-
somes. That situation is detrimental to the cell and can result in formation
of autophagosomal vacuoles [95]. This occurs in s-IBM muscle ﬁbers, as
well as in neurons of some neurodegenerative disorders (reviewed in
[3,26,91,95]). Although autophagic vacuoles associatedwith accumulated
lysosomal-membranous structureswithin s-IBMmuscleﬁbers have been
associated with s-IBM pathology for many years, the mechanism of their
formationwas notwell understood. Our recent studies have demonstrat-
ed that in s-IBMmuscle ﬁbers there is increased formation and “matura-
tion” of pathologic vacuolar autophagosomes [81]. These observations
suggested that excessive activatedmacroautophagy is an important factor
leading to formation of the vacuoles.
In addition to activated macroautophagy in s-IBM muscle ﬁbers, our
recent studies provided important evidence that autophagy related to
lysosomal function is diminished [81]. Those changes appeared to be
speciﬁc to s-IBM, becausewe found in polymyositismuscleﬁbers that ly-
sosomal activities were actually increased [81], as did others (referenced
in [81]), thereby suggesting that the seemingly similar lymphocytic in-
ﬂammation present in both s-IBM and PM might not contribute to im-
pairment of the autophagic/lysosomal degradation in s-IBM.
Impaired autophagy in s-IBMmuscle ﬁbers could be, at least partial-
ly, responsible for some of the abnormal accumulation of various pro-
teins, including Aβ, α-syn, BACE1 and tau, all reported to be degraded
through autophagy [52,91,100,101]. Of uncertain pathogenic signiﬁ-
cance, Aβ has been found to be produced within the autophagosomes
[95,102].5.3. Abnormalities of p62 and NBR1
Two partner proteins, p62 and NBR1 (neighbor of BRCA1 gene 1),
which are both shuttle proteins transporting polyubiquitinated pro-
teins to either proteasomal or lysosomal degradation [103–105], are
greatly increased in s-IBM muscle ﬁbers [72,106], where they
accumulate in the p-tau-containing PHFs structures. In AD neuroﬁ-
brillary tangles (NFTs) and Lewy bodies of Parkinson-disease, p62
was found accumulated in those ubiquitinated inclusions [107]. In
AD brain, p62 localized in NFTs was associated with phosphorylated
tau (p-tau) [107]. Our recent studies similarly demonstrated that in
s-IBM muscle both p62 and NBR1 are increased at both the protein
and mRNA levels, and are strongly accumulated in aggregates within
muscle ﬁbers, where they closely colocalize with p-tau by both the
light- and electron-microscopic immunocytochemistry [72,106].
This is another example of impaired protein degradation in s-IBM
muscle ﬁbers. It is of interest that it was recently reported that
a) NBR1 is phosphorylated by GSK-3ß, b) proper phosphorylation
of NBR1 prevents its aggregation, and c) in s-IBM NBR1 is hypo-
phosphorylated [108]. The study is of interest because some other
proteins present in s-IBM appear hyperphosphorylated by GSK-3ß
[50,109], which might suggest that some type of modiﬁcation of
NBR1 prevents its proper phosphorylation.5.4. Mitochondrial abnormalities, including abnormal mitophagy
Mitochondrial abnormalities, including ragged-red ﬁbers [110],
cytochrome-oxidase (COX) negative muscle ﬁbers (at a given trans-
verse level), and multiple mitochondrial DNA deletions, are more com-
mon in s-IBM muscle than expected for the patient's age (reviewed in
[34]). Other common abnormalities in the s-IBM muscle biopsy are:
a) very enlarged “giant” mitochondria, many of which have paucity of
cristae (Askanas et al, unpublished observation), and b) many mito-
chondria having paracrystalline inclusions. An antioxidant DJ-1 [111]
is an important mitochondrial protective agent (referenced in [39]).
DJ-1 was demonstrated quantitatively increased in s-IBMmuscle ﬁbers,
where it is highly oxidized and abnormally accumulated in mitochon-
dria [39], suggesting that the increased DJ-1 may be attempting to mit-
igatemitochondrial oxidative damage, but may be ineffective because it
is itself excessively oxidized.
Downregulated expression of complex I of the mitochondrial respi-
ratory chain, and mitochondrial DNA rearrangements in the majority
of individual respiratory-deﬁcient muscle ﬁbers have recently been
reported in s-IBM [112]. Those authors reported a correlation between
the number of T-lymphocytes and macrophages residing in muscle tis-
sue and the abundance of respiratory-deﬁcient muscle ﬁbers [112]. We
have not observed any correlation between COX-negative muscle ﬁbers
and mononuclear inﬂammation in s-IBM muscle ﬁbers [113].
In general, the mechanisms causing mitochondrial abnormalities in
s-IBM are not clariﬁed, but possibilities include: a) toxic soluble oligo-
mers of Aβ42, α-syn, p-tau, or other proteins; b) factors related to the
demonstrated oxidative and ER stresses; and c) abnormal autophagy.
Our newest studies point to the abnormalities of mitophagy, a process
involving degradation of mitochondria through the lysosomal system
[114–117]. Abnormal mitophagy has also been linked to aging and var-
ious neurodegenerative disorders (reviewed in [116,118]).
Cellular elimination of dysfunctional mitochondria through
mitophagy involves sequestration of mitochondria into LC3-II-
containing autophagosomes, which subsequently deliver them to ly-
sosomes for degradation [116–118]. The mitophagy receptor Bcl-2
adenovirus E1B19 19-kDa interacting protein (Bnip3) through its
homodimerization and subsequent binding of its dimer to LC3 en-
ables recruitment of damaged mitochondria to the autophagosomes
[119].
Mitochondrial dynamics importantly participate in the regulation of
mitophagy; increasedmitochondria ﬁssion is necessary formitochondrial
degradation, but enhanced mitochondria fusion results in mitochondrial
enlargement that obstructs their clearance [117,120,121]. We have re-
cently a) immunolocalized Bnip3 andMfn1, amarker ofmitochondria fu-
sion, in s-IBM muscle ﬁbers and control muscle ﬁbers, and b) studied
Bnip3 and Mfn1, in mitochondria isolated from s-IBM and age-matched
normal-control muscle biopsies, and in c) analyzed Bnip3 and Mfn1
mRNAs in total muscle homogenates by real-time PCR [122].
Our studies showed that in s-IBM as compared to controls, there
was a) a signiﬁcant increase of both Bnip3-dimer and of Bnip3
mRNA, and b) a signiﬁcant increase of Mfn1, its mRNA [122] and
Nogalska et al. in preparation. Interestingly, in s-IBM, Bnip3 was ac-
cumulated in the form of aggregates within muscle-ﬁbers, where it
closely co-localized with LC3 (Fig. 2).
By immuno-electron-microscopy, Bnip3 was mainly located on the
outer mitochondrial membrane (Fig. 3) and it closely co-localized
with LC3 within very abnormal mitochondria (Fig. 3).
(We were not able to immunohistochemically detect Bnip3 in either
normal or diseased control muscle biopsies [in those biopsies, LC3 has
been shown negative by us previously [81]]). Interestingly, Bnip3 and
Mfn1 were strongly immunoreactive at the periphery of ragged-red ﬁ-
bers, whichwas not s-IBM-speciﬁc (Fig. 2).We previously demonstrated
that in various diseased humanmuscle, α-syn and parkin accumulate in
ragged-redﬁbers (reviewed and illustrated in [26]).We propose that ab-
normal mitochondria within ragged-red ﬁbers, in various diseases
Fig. 2. Light-microscopic immunolocalization of Bnip3 andMfn1.Upper row. Immunolocalization of Bnip3 andMfn1 in ragged-red ﬁbers. Immunostainnings and Engel-trichrome staining
were performed on serial transverse sections. Ragged-red ﬁbers are identiﬁed as having a red staining at the periphery of the ﬁber, which is associatedwith the collection of very enlarged
abnormalmitochondria [107]. Increased staining of both Bnip3 andMfn1 occurswithin abnormalmitochondria of the ragged-redﬁbers. All ×900.Middle row. Single and double-immuno-
labeling of Bnip3 indicates its strong accumulation in the form of various-sized aggregates in s-IBM muscle ﬁbers. In a double-labeled example, Bnip3 closely co-localizes with LC3, sug-
gesting its presencewithin the autophagosomes. All ×1400. Lower row. Single and double-immuno-labeling ofMfn1 in s-IBMmuscle ﬁbers indicates its strong accumulation in the formof
various-sized aggregates. In a double-labeled example, aggregates of Mfn1 closely co-localize with Bnip3. All ×2500.
Fig. 3. Single anddouble gold-immuno-electron-microscopy of Bnip3 andMfn1 in s-IBMmitochondria. Gold particles indicate that Bnip3 is localized at the periphery of themitochondrion
in the form of small clusters; in one very abnormal mitochondrion, probably designed for autophagosomal degradation, Bnip3 is intermingled with LC3 (Bnip3 6 nm gold particles, LC3
12 nm gold particles). Mfn1 is increased at the site where the mitochondria are presumably fusing, as suggested by concentration of 5 nm gold particles at those sites. All 82,000.
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640 V. Askanas et al. / Biochimica et Biophysica Acta 1852 (2015) 633–643including s-IBM, are destined for autophagic degradation, and parkin is
recruited to facilitate their clearance, as has been reported in other sys-
tems (reviewed in [118]).
In s-IBM muscle the increase of mitophagy receptor Bnip3 and its
binding with LC3 suggest that the signal for mitochondria transport to
the autophagosomes is preserved and even increased. However, in s-
IBM muscle the mitochondrial degradation is likely impaired due to
i) enlargement of the mitochondria resulting from their increased fu-
sion; ii) accumulation of Bnip3 in the form of aggregates, which might
inhibit its activity; but mainly due to iii) our previously-demonstrated
lysosomal inhibition, all of which might lead to the accumulation of
damaged mitochondria. It has been demonstrated recently that experi-
mental overexpression of UBB+1 increases mitochondrial fusion pro-
teins, but it decreases mitochondrial ﬁssion proteins [123]. UBB+1 is
accumulated in s-IBM muscle ﬁbers [96], but whether or not UBB+1
increase has an inﬂuence on mitochondrial fusion in s-IBM is not cur-
rently known.
The mitochondrial abnormalities in s-IBM muscle seem likely to
contribute to the muscle-ﬁber malfunction, degeneration, and weak-
ness. The importance of the mitochondrial unfolded protein response
(UPRmit), and the inﬂuence of mitochondria in protein homeostasis
have recently been emphasized [47,124].
6. Our experimentally-based treatment suggestions
Studies of the s-IBM muscle biopsies do not permit precise evalua-
tion of the causes and effects of various pathologies. Therefore, one of
our approaches is to explore molecular mechanisms participating in
the s-IBM pathogenesis by utilizing well-differentiated cultured normal
human muscle ﬁbers, whose cellular micro-environment we experi-
mentally modify to mimic various pathologic aspects of the s-IBM
muscle-ﬁber milieu. This provides our “IBM-Human Muscle Culture
Models (IBM-HM-TC-Models)” (details reviewed and illustrated in [25]
). Our studies utilizing these models demonstrate important relation-
ships and suggest important cross-talk between various molecular
events occurring in s-IBMmuscle ﬁbers, and they provide possibly rele-
vant models to evaluate the efﬁcacy of potential therapies for s-IBM.
(Others have utilized experimental transgenic mouse models, which
also have helped elucidate some aspects of the s-IBM pathogenesis.
Those were previously referenced in a detailed review [26].)
Several treatments trials in s-IBM were recently reviewed [13,15],
and thus are not going to be reviewed here.
Based on our IBM-culture models and various experimental AD
models, the following compounds can be considered for treating s-
IBM patients. Because, currently, we are most interested in decreasing
Aβ42 and its subsequent oligomerization, we are focusing on sodium
phenylbutyrate (NaPB) and lithium. Both are FDA-approved drugs,
which in our experimental models appeared very useful. We found
that NaPB was beneﬁcial in improving autophagosomal degradation.
6.1. Sodium phenylbutyrate (NaPB)
NaPB is an orally bioavailable small molecule approved by the FDA
for treatment of urea cycle-disorders [125,126]. Taken daily and long-
term by infants, children and adults, it is usually well-tolerated [126].
NaPB reportedly mimics the function of intracellular molecular chaper-
ones by preventing protein aggregation and oligomerization [127], in
addition to being a histone deacetylase inhibitor [125,126].
In our experimental humanmuscle tissue culture IBMmodel based on
inhibited autophagy (Autoph (−)-IBM-HM-TC-Model), treatment with
NaPB: a) virtually completely eliminated vacuolization; b) increased
activities of both cathepsins D and B; c) decreased NBR1 and p62;
d) substantially decreased Aβ42 and Aβ42 oligomerization; and
e) decreased γ-secretase activity [128]. All those parameters are substan-
tially increased both in s-IBM muscle ﬁbers and in our Autoph (−)-IBM-
HM-TC-Model [81,128]. Unblocking a defective lysosomal degradationas a possible therapeutic strategy for s-IBM and neurodegenerative dis-
eases was previously proposed [25,129], and experimental restoration
of cathepsin B, D, and L activity in transgenic AD mice resulted in Aβ
clearance and improved AD-like pathology in them [129]. Our results
show that NaPB improves lysosomal activity and ameliorates the conse-
quences of the impaired autophagy, providing a rationale for considering
NaPB as a putative drug for s-IBM patients, and possibly other neurode-
generative disorders with impaired lysosomal degradation.
These data provide a strong rationale for considering therapeutic tri-
als of s-IBM patients with NaPB.
6.2. Lithium
Lithiumwas reported to diminish tau and Aβ pathologies in various
experimental models of AD (reviewed in [130]). In a transgenic mouse
model whose skeletal muscle bears some aspects of IBM muscle ﬁbers,
lithiumwas reported to decrease tau phosphorylation through decreas-
ing activity of GSK-3β [131]. In cultured human muscle ﬁbers in our
AβPP-overexpressing IBMmodel (AβPP (+)-IBM-HM-TC-Model), lithium
signiﬁcantly decreased total AβPP, phosphorylated AβPP, and Aβ oligo-
mers [50]. In addition, lithium signiﬁcantly increased the inactive form
of GSK-3β [50]. Accordingly, treating s-IBM patients with lithium,
which is widely used in treating bipolar disorders in humans, might
be beneﬁcial if used in “adequate” and safe dosage.
6.3. Polyphenols
Polyphenols recently have been reported to beneﬁt experimental
mouse models of AD and an IBM-culture model. For example:
a) treatment with Resveratrol (trans-3,4′,5-trihydroxystilbene), an an-
tioxidant polyphenol and potent activator of SIRT1 (reviewed in [132]
), in our ER stress-induced cultured human muscle ﬁbers (ERS(+)-IBM-
HM-TC-Model) signiﬁcantly: i) decreased myostatin mRNA and protein,
whichwas associatedwith NF-κB de-acetylation (de-activation), and ii)
it increasedmuscle-ﬁber size [133], suggesting that resveratrolmight be
beneﬁcial in treating s-IBM patients if one can use a stable non-toxic
form in adequate dosage. b) Other phenolic compounds, including
curcumin and grape-seed-derived polyphenols have been reported to
decrease the amyloid-burden and Aβ ﬁbrilization in AD transgenic
mouse models and in vitro [134].
In the future other treatment approaches might include
a) mitochondria protective molecules, b) decreasing myostatin, and
c) decreasing the consequences of the ER stress.
Several approaches, including active and passive immunization
against Aβ42 have been proposed for treatment of AD but, despite
their possible effects in various AD mouse models, their usefulness for
patients is still unknown. Some of the trials had to be interrupted, either
because of detrimental side-effects or lack of the evident efﬁcacy. Those
studies were recently in [135,136]. Other approaches, which are also
being discussed as possible treatments of AD, are a) BACE-1 inhibitors,
and b) tau-immunotherapy, reviewed in [136,137]. However, their
application to human patients still remains unknown. If any of those
approaches will prove safe and beneﬁcial for AD patients, that would
justify treatment trials in s-IBM patients.
However, their possible toxicity and potential beneﬁts for s-IBM
patients are still not known.
7. Conclusion
In conclusion, s-IBM is a degenerativemuscle disease in which aging
appears to be a key risk factor. Severalmolecularmechanisms responsi-
ble formultiprotein aggregation and accumulationwithin s-IBMmuscle
ﬁbers were reviewed. Since anti-dysimmune treatments are generally
not effective, and were even reported to be detrimental for s-IBM
patients [12], it is not likely that s-IBM is a primary dysimmune/inﬂam-
matory disease. But as we have been proposing, accumulation of
641V. Askanas et al. / Biochimica et Biophysica Acta 1852 (2015) 633–643posttranslationally modiﬁed, misfolded proteins in the aging milieu of
s-IBMmuscle ﬁbersmight be perceived by the patient's immune system
as “foreign” (not “self”) and be responsible for inducing T-cell inﬂam-
mation in the s-IBM muscle. Accordingly, we feel that therapeutic
approaches should be directed toward decreasing degenerative compo-
nents of the s-IBM pathogenesis. Unfortunately, thus far the source of a
Fountain of Myo-Youth has not yet been identiﬁed.
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